Literature DB >> 20184665

CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma.

William A Kanner1, Louis B Brill, James W Patterson, Mark R Wick.   

Abstract

BACKGROUND: Atypical fibroxanthoma (AFX) is a pleomorphic spindle cell lesion of the skin; it is considered in the differential diagnosis with spindle cell malignant melanoma (MM) and sarcomatoid carcinoma/spindle cell squamous cell carcinoma (SCC). An optimum approach has yet to fully emerge with respect to the immunohistochemical discrimination of these lesions.
METHODS: Departmental archives from 1978 onwards were searched for clinicopathologically confirmed cases of AFX, MM and SCC. Immunostains for CD10, CD99 and p63 were performed in each case. Scored staining results were analyzed using Fisher's Exact Test.
RESULTS: Twenty-seven of 31 cases of AFX were positive for CD10, as compared with 3 of 22 SCCs and 0 of 20 MMs. CD10 positivity was preferentially associated with the diagnosis of AFX (p < 0.001). p63 reactivity was observed in 15/22 cases of SCCs, 5/31 AFXs and 1/20 MMs. CD99 reactivity was observed in 3/31 cases of AFX, 2/22 SCCs and 3/20 MMs.
CONCLUSION: CD10 positivity is relatively specific in this context for the diagnosis of AFX. Its utility is enhanced when only strong, diffuse membranocytoplasmic staining is considered as a positive result. In contrast to prior reports, p63 was not found to be highly sensitive for SCC. Similarly, CD99 showed no preferential staining of any single diagnostic group of lesions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20184665     DOI: 10.1111/j.1600-0560.2010.01534.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  7 in total

Review 1.  Soft Tissue Special Issue: Cutaneous Pleomorphic Spindle Cell Tumors.

Authors:  Thomas Brenn
Journal:  Head Neck Pathol       Date:  2020-01-16

2.  Double primary malignant fibrous histiocytoma and squamous cell carcinoma of the larynx treated with laser laryngeal conservation surgery.

Authors:  P D Karkos; S Dova; S Sotiriou; K Markou; I Kostopoulos
Journal:  Ecancermedicalscience       Date:  2016-04-25

Review 3.  p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer.

Authors:  Artem Smirnov; Lucia Anemona; Flavia Novelli; Cristina M Piro; Margherita Annicchiarico-Petruzzelli; Gerry Melino; Eleonora Candi
Journal:  Int J Mol Sci       Date:  2019-11-17       Impact factor: 5.923

4.  Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases.

Authors:  David Suster; Michael Michal; Huiya Huang; Shira Ronen; Stephanie Springborn; Maria Debiec-Rychter; Steven D Billings; John R Goldblum; Brian P Rubin; Michal Michal; Saul Suster; A Craig Mackinnon
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

5.  p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Authors:  Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi
Journal:  J Exp Med       Date:  2013-02-18       Impact factor: 14.307

Review 6.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

Review 7.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.

Authors:  Leigh A Compton; George F Murphy; Christine G Lian
Journal:  Dermatopathology (Basel)       Date:  2015-04-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.